Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
The Methodist Hospital System
Center for Cell and Gene Therapy, Baylor College of Medicine
Information provided by (Responsible Party):
Stephen Gottschalk, Baylor College of Medicine
ClinicalTrials.gov Identifier:
NCT00889954
First received: April 24, 2009
Last updated: September 12, 2016
Last verified: September 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: June 2030
  Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)